| DC-CIK与rmhTNF腹腔灌注治疗晚期胃癌恶性腹水的临床对照研究 |
| |
| 引用本文： | 丁园,陈玉强,李月,米彦军,叶燕华,李强. DC-CIK与rmhTNF腹腔灌注治疗晚期胃癌恶性腹水的临床对照研究[J]. 实用肿瘤学杂志, 2015, 29(1): 12-16. DOI: 10.11904/j.issn.1002-3070.2015.01.003 |
| |
| 作者姓名： | 丁园 陈玉强 李月 米彦军 叶燕华 李强 |
| |
| 作者单位： | 厦门大学附属成功医院,中国人民解放军第一七四医院肿瘤治疗中心(厦门 361003) |
| |
| 基金项目： | 南京军区医学科技创新课题(10MA068);厦门市科技计划创新项目(3502Z20134026、3502z20144034) |
| |
| 摘 要： | 目的 探讨重组人肿瘤坏死因子(Recombinant mutant human tumor necrosis factor,rmhTNF)腹腔灌注及自体树突状细胞(Dendritic cell,DC)联合细胞因子诱导的杀伤细胞(Cytokine induced killer,CIK)腹腔灌注治疗晚期胃癌恶性腹腔积液的临床疗效差异。方法 将48例确诊的晚期胃癌合并腹水患者,随机分为DC-CIK组、rmhTNF组。治疗后1个月观察两组不良反应发生情况,评估治疗后患者临床受益反应(CBR)、腹水控制率(RR)、免疫指标、肿瘤标志物(CEA、CA199、CA724)水平等疗效,观察至疾病进展时间(TTP)。结果 DC-CIK组RR、CBR分别为66.67%、83.30%,rmhTNF组RR、CBR分别为58.33%、75.00%,两组间差异有统计学意义(P＜0.05)。治疗后两组患者CA724水平均较治疗前降低,差异有统计学意义(P=0.015);治疗前后两组间各肿瘤标志物均无显著差异(P＞0.05)。DC-CIK组治疗后患者外周血CD3+、CD4+、NK细胞较治疗前明显增多(P＜0.05),CD8+细胞数量无明显变化(P=0.55)。rmhTNF组治疗后NK细胞较治疗前明显增多(P=0.03),T淋巴细胞亚群无明显变化(P＞0.05)。随访1年,DC-CIK组患者TTP为7.1个月,rmhTNF组为5.8个月,差异有统计学意义(P=0.02)。结论 DC-CIK及rmhTNF腹腔灌注两种治疗方案均能有效控制恶性腹水,自体DC-CIK治疗在增强机体特异性免疫抗肿瘤方面更显优势。
|
| 收稿时间： | 2014-08-17 |
Clinical controlled trial of the advanced gastric patients with ascites by intra-abdominal infusion of DC-CIK or rmhTNF |
| |
| DING Yuan,CHEN Yuqiang,LI Yue,MI Yanjun,YE Yanhua,LI Qiang. Clinical controlled trial of the advanced gastric patients with ascites by intra-abdominal infusion of DC-CIK or rmhTNF[J]. Journal of Practical Oncology, 2015, 29(1): 12-16. DOI: 10.11904/j.issn.1002-3070.2015.01.003 |
| |
| Authors: | DING Yuan CHEN Yuqiang LI Yue MI Yanjun YE Yanhua LI Qiang |
| |
| Affiliation: | Department of Oncology,No.174 Hospital of PLA,Xiamen 361003,China |
| |
| Abstract: | Objective This study is to explore the differences in the curative effect of intra-abdominal infusion between Recombinant mutant human tumor necrosis factor and Dendritic cell-Cytokine induced killer.Methods We selected 48 advanced gastric cancer patients with ascites.Those patients were randomized into two groups:DC-CIK group and rmhTNF group.After one month treatment,we observed the adverse events both two groups,and evaluated the clinical beneficial responses,the responsive rate,the tumor indicators′ level,the immune indexes and the time of tumor progression.Results In the DC-CIK group,the RR and the CBR were 83.3% and 66.67%,respectively;while in the rmhTNF group,they were 58.33% and 75%,respectively.The difference between two groups was statistically significant(P＜0.05).Only CA724 decreased after treatment in two groups(P=0.015).There were no significant differences of tumor markers between the two groups before and after treatment(P＞ 0.05).The ratios of CD3+、CD4+、NK cells distinctly increased after treatment(P＜0.05),but the ratio of CD8+ cell was no obvious difference in DC-CIK group(P=0.551);The ratio of NK cells increased obviously after treatment(P=0.027),but the ratios of CD3+ and CD4+ were similar as previous in rmhTNF group(P＞0.05).One year follow-up of the time to progression(TTP)was 7.1 months in DC-CIK group,and 5.8 months in TNF group,which was statistically significant(P=0.02).Conclusion Both rmhTNF and DC-CIK can improve the efficacy for the patients with malignant ascites caused by gastric cancer.However,DC-CIK immunotherapy shows better active effect on improvement of specific immune function. |
| |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《实用肿瘤学杂志》浏览原始摘要信息 |
|
点击此处可从《实用肿瘤学杂志》下载免费的PDF全文 |
|
